Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study of Sevelamer Carbonate in CKD Patients on Hemodialysis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sevelamer (Primary)
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Genzyme Corporation; Sanofi
- 01 Apr 2014 New trial record
- 01 Sep 2010 Primary endpoint 'Phosphate-levels' has been met.